Tonix announces preclinical data for TNX-1700 in gastric cancer models published in Cancer Cell

Tonix Pharmaceuticals Holding Corp.

mTNX-1700 plus anti-PD-1 increased survival and decreased metastases in gastric cancer animal models vs anti-PD-1 alone.
Treatment associated with activation of CD8+ T cells and limiting neutrophil-mediated immune evasion.
Human version TNX-1700 (hTFF2-HSA) is in preclinical development for gastric and colorectal cancers.
Collaboration with Columbia University's Medical School; paper titled 'A CXCR4 Partial Agonist, Improves Immunotherapy...'.
Data support further development of TNX-1700 to overcome resistance to anti-PD-1 immunotherapy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.